argenx SE
ARGXDrugs in Pipeline
13
Phase 3 Programs
9
Upcoming Catalysts
7
Next Catalyst
Jul 30, 2026
21dMarket Overview
Stock performance and key metrics
9 upcoming, 1 past
How ARGX's past catalysts played out
Efgartigimod IV
Generalized Myasthenia Gravis
ARGX-113
Pemphigus Vulgaris
Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
EFG PH20 SC
Active Idiopathic Inflammatory Myopathy
IVIG (Intravenous Immunoglobulin)
Multifocal Motor Neuropathy (MMN)
Efgartigimod
Postural Orthostatic Tachycardia Syndrome
empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy
Prednisone
Bullous Pemphigoid
Empasiprubart IV
Chronic Inflammatory Demyelinating Polyneuropathy
ARGX-119
Amyotrophic Lateral Sclerosis
ARGX-117
Multifocal Motor Neuropathy
efgartigimod PH20 SC in stage B
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ARGX-119 IV
Spinal Muscular Atrophy (SMA)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efgartigimod IV | Phase 3 | Generalized Myasthenia Gravis | - | - |
ARGX-113 | Phase 3 | Pemphigus Vulgaris | - | - |
Efgartigimod PH20 SC | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
EFG PH20 SC | Phase 3 | Active Idiopathic Inflammatory Myopathy | - | - |
IVIG (Intravenous Immunoglobulin) | Phase 3 | Multifocal Motor Neuropathy (MMN) | - | - |
Efgartigimod | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Prednisone | Phase 3 | Bullous Pemphigoid | - | - |
Empasiprubart IV | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
ARGX-117 | Phase 2 | Multifocal Motor Neuropathy | - | - |
efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
ARGX-119 IV | Phase 2 | Spinal Muscular Atrophy (SMA) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in argenx SE's drug pipeline?→
CatalystAlert tracks 13 drug candidates in argenx SE's (ARGX) pipeline across Phase 3, Phase 2. Its lead program is Efgartigimod IV (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is argenx SE's next FDA catalyst?→
argenx SE's (ARGX) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARGX biotech catalysts?→
Add ARGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow argenx SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.